LOS ANGELES--(BUSINESS WIRE)--Jan. 27, 2006--BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced today the availability of a new Q&A interview with executives of Callisto Pharmaceuticals Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug therapies in the fight against cancer and other serious health threats. In the written interview, the Callisto executives discuss the Company's recently announced exclusive licensing of a new drug class called Degrasyn, whose novel activity is designed to attack a wide range of cancer tumors.
